According to a major international study, Switzerland has once again fallen behind other European countries in terms of access to new innovative medicines – from sixth to seventh place. Particularly worrying is the fact that, compared to Germany, only around half as many new innovative medicines are reimbursed as standard via the specialty list.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Digital dermatology: innovative project examples
AI and eHealth tools in HS care
- Mantle cell lymphoma
Recurrence after BTK inhibition – prognostic factors and treatment options
- Dementia risk with type 2 diabetes
SGLT2 inhibitors with advantages vs. DPP4 inhibitors
- T helper 1 cells
Differentiation and activation of Th1 cells – a multi-omics approach
- Cannabis for schizophrenia
CBD pre-treatment could exacerbate side effects
- Type 2 diabetes: cardiovascular risk reduction is realistic
Modern active ingredients and lifestyle – every step counts
- Case study
8-year-old girl with Pätau syndrome aka trisomy 13
- Lichen sclerosus